DEC 17 2002

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231,

on <u>December 13</u>, 2002

By: Lois Miller

1600 0500

**PATENT** 

Atty. Docket No. DX01052K1

RECEIVED CN 028008

DEC 2 7 2002

**TECH CENTER 1600/2900** 

#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

A. Neil BARCLAY, et al.

Serial No.: 10/009,445

IA Filing Date: May 11, 2000

For: MAMMALIAN PROTEINS;

**RELATED REAGENTS AND** 

**METHODS** 

Examiner: not yet assigned

Art Unit: not yet assigned

INFORMATION DISCLOSURE STATEMENT

Palo Alto, California 94304

December / 3 , 2002

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

The materials as listed in the attached modified PTO 1449 form are brought to the Examiner's attention pursuant to the duty of disclosure under 37 C.F.R. § 1.56, § 1.97, and § 1.98. Also enclosed is the PCT Search Report, dated November 7, 2000, in connection with this matter. "X" references cited in this search report are listed in the attached PTO 1449 form.

Citation of these documents should not be construed as a representation that the documents are in fact material or are in fact prior art with respect to the instant invention. The Examiner should not make any inference relating to the relative pertinence of cited references based upon the order in which the art is presented. Citation of these documents should not be construed as a representation that an exhaustive search has been made or that more pertinent art may not be in existence.

Applicants request that the Examiner fully consider the art cited in the attached modified PTO 1449 form. Applicants further request that the Patent and Trademark Office list all such art on the front of any patent issuing from this application.

Since this Information Disclosure Statement is being filed before receiving the first Office action, applicants believe no fee is required for filing this document; however, if such a fee is required the Commissioner is hereby authorized to charge DNAX Research Institute's Deposit Account No. 04-1239.

13 . 2002 December

Respectfully submitted,

Attorney for Applicants

Reg. No. 41,201

**Enclosures:** 

Modified PTO 1449 form (2 pages)

PCT Search Report, dated November 7, 2000 (10 pages)

References AA - AQ (17 refs.)

### **RECEIVED**

DEC 2 7 2002

Sheet <u>1</u> of <u>2</u>

					TECH CEN	TER 1600	)/2900	Sheet	1 of 2	
FORM PTO-1449 U.S. DEPARTMENT OF COMME PATENT AND TRADEMARK OF					ATTY. DOCKET NO.: DX01052K1		SERIAL NO.: 10/009,445			
	ORM	ATION DISCLOSUR	RE STAT	EMENT	APPLICANT:  A. Neil BARCLAY, et al.					
- mm N					IA FILING DATE: GROUP:					
(Use several sheets if necessary)			Y)	May 11, 2	Not yet assigned					
U.S. PATENT DOCUMENTS										
MINER		DOCUMENT NUMBER	DATE	NAME		CLASS	SUB-	FILING I		
INITIAL	<del> </del>					ļ <u>.</u>	CLASS	APPRO	PRIATE	
	FOREIGN PATENT DOCUMENTS									
		DOCUMENT	DATE	COUNTRY		CLASS	SUB- CLASS	TRANSI YES	LATION TNO	
		NUMBER	2/10/00	PCT	<del></del>		CLAGO	X	110	
	AA	WO 00/06698	1			<u> </u>		L	<u> </u>	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)										
,	AB	Alexander B.H. Bakker, et al., <u>Proc Natl Acad Sci, USA</u> , 96(17):9792-9796, August 17, 1999. "Myeloid DAP-12-associating lectin (MDL)-1 is a cell surface receptor involved in the activation of myeloid cells"								
	AC	J. Fernando Bazan, <i>et al.</i> , <u>NATURE</u> , 379:591, February 15, 1996. "A newly defined interleukin-1?"								
	AD	Frank Borriello, et al., <u>J Immunol</u> , 158(10):4548-4554, May 15, 1997. "MRC OX-2 defines a novel T cell costimulatory pathway"								
	AE	Frank Borriello, et al.,.Mamm Genome, 9(2):114-118, February 1998. "Characterization and localization of Mox2, the gene encoding the murine homolog of the rat MRC OX-2 membrane glycoprotein"								
	AF	Kerry S. Campbell & Marco Colonna, Int J Biochem Cell Biol, 31(6):631-636, June 1999. "DAP12 a key accessory protein for relaying signals by natural killer cell receptors"								
	AG	Irwin M. Chaiken & William V. Williams, <u>Trends Biotechnol</u> , 14(10):369-375, October 14, 1996. "Identifying structure-function relationships in four-helix bundle cytokines: towards de novo mimetics design"								
	АН	Pierre Gosselin, et al., <u>J Leukoc Biol</u> , 66(1):165-171, July 1999. "Induction of DAP12 phosphorylation, calcium mobilization, and cytokine secretion by Ly49H"								
	Al	Joan K. Heath, et al., <u>Proc Natl Acad Sci U S A</u> , 94(2):469-474, January 21, 1997. "The human A33 antigen is a transmembrane glycoprotein and a novel member of the immunoglobulin superfamily"								
	AJ	Jeffrey M. Herz, et al., <u>J Recept Signal Transduct Res.</u> , 17(5):671-776, September 1997. "Molecular approaches to receptors as targets for drug discovery"								
	AK	James N. Ihle, et al. Stem Cells, 15 (Suppl 1):105-11, 1997.  "Jaks and Stats in cytokine signaling"								
	AL	Lewis L. Lanier, et al., <u>Immunity</u> , 8(6):693-701, June 1998. "Association of DAP12 with activating CD94/NKG2C NK cell receptors"								
EXAMINER				DATE C	CONSIDERED					
*EXAMINE through cit applicant.	*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.									

# O 1 P 2002 26

**FORM PTO-1449** 

### **RECEIVED**

DEC 2 7 2002

TECH CENTER 1600/2900

Sheet 2 of 2

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

DX01052K1

APPLICANT:

SERIAL NO.: 10/009,445

## INFORMATION DISCLOSURE STATEMENT FOR PATENT

(Use several sheets if necessary)

A. Neil BARCLAY, et al.

IA FILING DATE: GROUP:

May 11, 2000 Not yet assigned

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)						
AM	Lewis L. Lanier, et al., <u>Nature</u> , 391(6668):703-707, February 12, 1998. "Immunoreceptor DAP12 bearing a tyrosine-based activation motif is involved in activating NK cells"					
AN	David E. Levy, Cytokine Growth Factor Rev., 8(1):81-90, March 1997. "The house that JAK/STAT built"					
AO	Miguel Lopez-Botet & Teresa Bellon, <u>Curr Opin Immunol</u> , 11(3):301-307, June 1999. "Natural killer cell activation and inhibition by receptors for MHC class I"					
АР	M. Marra, et al., <u>Database EMBL Sequences</u> , <u>Online!</u> , Accession No. Al613766, April 26, 1999. Definition: vh96g05.y1 Barstead mouse myotubes MPLRB5 Mus musculus cDNA clone IMAGE:902168 5', mRNA sequence.					
AQ	Sandy Preston, et al., <u>Eur J Immunol</u> , 27(8):1911-1918, August 1997. "The leukocyte/neuron cell surface antigen OX2 binds to a ligand on macrophages"					
AR	Olli Silvennoinen, <i>et al.</i> , <u>APMIS</u> , 105(7):497-509, July 1997. "Cytokine receptor signal transduction through Jak tyrosine kinases and Stat transcription factors"					
EXAMINER		DATE CONSIDERED				

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.